Status of the phase II study of Amphinex® in head and neck cancer patients

Posted on Mar 30, 2012

Oslo, 29 March 2012 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today status for the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients. All preparations necessary to include patients are completed. The National Center for Tumor Diseases (NCT), University Hospital Heidelberg, and Ludwig Maximilian University Munich,Germany, have started the screening of patients.